Irritable Bowel Syndrome

Healio Gastroenterology presents the following report on the top peer-tested stories in June.

Patients with irritable bowel syndrome who engaged in severe food avoidance and restriction experienced more severe IBS symptoms and a reduced quality of life, according to study results.

Compared with placebo, LinZess significantly decreased abdominal symptoms such as bloating, discomfort and pain in patients with irritable bowel syndrome with constipation, according to results published in the American Journal of Gastroenterology.

Researchers observed clinically and statistically meaningful improvements with Trulance in patients with chronic idiopathic constipation and irritable bowel syndrome with constipation with reduced quality of life.

In this video exclusive, Sabine Hazan, MD, discussed what stool says about an individual’s health, the role of the gut microbiome in overall health and things COVID-19 survivors and long-haulers need to pay attention to.

Mucosal biofilms are endoscopic features in patients with irritable bowel syndrome and ulcerative colitis with disrupted bile acid metabolism and bacterial dysbiosis, according to a study in Gastroenterology.

In this video exclusive, Qi T. Yu, DO, from Loma Linda University Health, discussed how laxatives at baseline impacted the outcomes of subcutaneous Relistor in patients with advanced illness and opioid-induced constipation.

In honor of World Digestive Health Day, Healio Gastroenterology presents the following report on the latest top stories from Digestive Disease Week.

Trulance improved quality of life among patients with irritable bowel syndrome and chronic constipation, Greg Sayuk, MD, MPH, Washington University at St. Louis, told Healio.

In this video exclusive, Brian E. Lacy, MD, from Mayo Clinic, Jacksonville, Florida, spoke about a survey of patients with IBS with constipation in the era of COVID-19.